CEACAM1-3S drives melanoma cells into NK cell-mediated cytolysis and enhances patient survival

Cancer Research

Volumn 75, Issue 9, 2015, Pages 1897-1907

  Ullrich, Nico ^a,b   Heinemann, Anja ^a,b   Nilewski, Elena ^c   Scheffrahn, Inka ^c   Klode, Joachim ^a,b   Scherag, Andre ^d   Schadendorf, Dirk ^a,b   Singer, Bernhard B ^c   Helfrich, Iris ^a,b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1 3L; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1 3S; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1 4L; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1 4S; LYMPHOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 RELATED MOLECULE A; MEMBRANE PROTEIN; UL16 BINDING PROTEIN 2; UNCLASSIFIED DRUG; CD66 ANTIGENS; CELL ADHESION MOLECULE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HLA ANTIGEN CLASS 1; ISOPROTEIN; LEUKOCYTE ANTIGEN; LIGAND; MHC CLASS I-RELATED CHAIN A; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; SIGNAL PEPTIDE; ULBP2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA CELL; MELANOMA CELL LINE; NATURAL KILLER CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR CELL DESTRUCTION; UPREGULATION; CELL MEMBRANE; CYTOTOXICITY; DISEASE COURSE; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; MIDDLE AGED; MORTALITY; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MEMBRANE; CYTOTOXICITY, IMMUNOLOGIC; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; GPI-LINKED PROTEINS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; LIGANDS; MALE; MELANOMA; MIDDLE AGED; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PROTEIN ISOFORMS; TRANSFECTION; UP-REGULATION;

EID: 84938429232     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1752     Document Type: Article

References (49)

1. Schadendorf D, Hauschild A. Melanoma in 2013: Melanoma-the run of success continues. Nat Rev Clin Oncol 2014; 11: 75-6.
2. Edward M. Integrins and other adhesion molecules involved in melanocytic tumor progression. Curr Opin Oncol 1995; 7: 185-91.
3. Sapoznik S, Ortenberg R, Schachter J, Markel G. CEACAM1 in malignant melanoma: a diagnostic and therapeutic target. Curr Top Med Chem 2012; 12: 3-10.
4. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991; 5: 344-66.
5. Huang J, Simpson JF, Glackin C, Riethorf L, Wagener C, Shively JE. Expression of biliary glycoprotein (CD66a) in normal and malignant breast epithelial cells. Anticancer Res 1998; 18: 3203-12.
6. Huang J, Hardy JD, Sun Y, Shively JE. Essential role of biliary glycoprotein (CD66a) in morphogenesis of the human mammary epithelial cell line MCF10F. J Cell Sci 1999; 112 (Pt 23): 4193-205.
7. Muller MM, Singer BB, Klaile E, Obrink B, Lucka L. Transmembrane CEACAM1 affects integrin-dependent signaling and regulates extracellular matrix protein-specific morphology and migration of endothelial cells. Blood 2005; 105: 3925-34.
8. Singer BB, Scheffrahn I, Heymann R, Sigmundsson K, Kammerer R, Obrink B. Carcinoembryonic antigen-related cell adhesion molecule 1 expression and signaling in human, mouse, and rat leukocytes: evidence for replacement of the short cytoplasmic domain isoform by glycosylphosphatidylinositol-linked proteins in human leukocytes. J Immunol 2002; 168: 5139-46.
9. Singer BB, Klaile E, Scheffrahn I, Muller MM, Kammerer R, Reutter W, et al. CEACAM1 (CD66a) mediates delay of spontaneous and Fas ligand-induced apoptosis in granulocytes. Eur J Immunol 2005; 35: 1949-59.
10. Neumaier M, Paululat S, Chan A, Matthaes P, Wagener C. Biliary glycoprotein, a potential human cell adhesion molecule, is down-regulated in colorectal carcinomas. Proc Natl Acad Sci U S A 1993; 90: 10744-8.
11. Luo W, Tapolsky M, Earley K, Wood CG, Wilson DR, Logothetis CJ, et al. Tumor-suppressive activity of CD66a in prostate cancer. Cancer Gene Ther 1999; 6: 313-21.
12. Riethdorf L, Lisboa BW, Henkel U, Naumann M, Wagener C, Loning T. Differential expression of CD66a (BGP), a cell adhesion molecule of the carcinoembryonic antigen family, in benign, premalignant, and malignant lesions of the human mammary gland. J Histochem Cytochem 1997; 45: 957-63.
13. Ebrahimnejad A, Streichert T, Nollau P, Horst AK, Wagener C, Bamberger AM, et al. CEACAM1 enhances invasion and migration of melanocytic and melanoma cells. Am J Pathol 2004; 165: 1781-7.
14. Thies A, Berlin A, Brunner G, Schulze HJ, Moll I, Pfuller U, et al. Glycoconjugate profiling of primary melanoma and its sentinel node and distant metastases: implications for diagnosis and pathophysiology of metastases. Cancer Lett 2007; 248: 68-80.
15. Thom I, Schult-Kronefeld O, Burkholder I, Schuch G, Andritzky B, Kastendieck H, et al. Expression of CEACAM-1 in pulmonary adenocarcinomas and their metastases. Anticancer Res 2009; 29: 249-54.
16. Singer BB, Scheffrahn I, Obrink B. The tumor growth-inhibiting cell adhesion molecule CEACAM1 (C-CAM) is differently expressed in proliferating and quiescent epithelial cells and regulates cell proliferation. Cancer Res 2000; 60: 1236-44.
17. Singer BB, Scheffrahn I, Kammerer R, Suttorp N, Ergun S, Slevogt H. Deregulation of the CEACAM expression pattern causes undifferentiated cell growth in human lung adenocarcinoma cells. PLoS ONE 2010; 5: e8747.
18. Stern N, Markel G, Arnon TI, Gruda R, Wong H, Gray-Owen SD, et al. Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1. J Immunol 2005; 174: 6692-701.
19. Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, Drize O, et al. CD66a interactions between human melanoma and NK cells: anovel classI MHC-independent inhibitory mechanism of cytotoxicity. J Immunol 2002; 168: 2803-10.
20. Markel G, Wolf D, Hanna J, Gazit R, Goldman-Wohl D, Lavy Y, et al. Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions. J Clin Invest 2002; 110: 943-53.
21. Markel G, Seidman R, Stern N, Cohen-Sinai T, Izhaki O, Katz G, et al. Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions. J Immunol 2006; 177: 6062-71.
22. Chen Z, Chen L, Baker K, Olszak T, Zeissig S, Huang YH, et al. CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells. J Exp Med 2011; 208: 2633-40.
23. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010; 235: 267-85.
24. Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008; 27: 5944-58.
25. Barnett TR, Drake L, Pickle W. Human biliary glycoprotein gene: characterization of a family of novel alternatively spliced RNAs and their expressed proteins. Mol Cell Biol 1993; 13: 1273-82.
26. Beauchemin N, Draber P, Dveksler G, Gold P, Gray-Owen S, Grunert F, et al. Redefined nomenclature for members of the carcinoembryonic antigen family. Exp Cell Res 1999; 252: 243-9.
27. Gray-Owen SD, Blumberg RS. CEACAM1: contact-dependent control of immunity. Nat Rev Immunol 2006; 6: 433-46.
28. Fiori V, Magnani M, Cianfriglia M. The expression and modulation of CEACAM1 and tumor cell transformation. Ann Ist Super Sanita 2012; 48: 161-71.
29. Obrink B. On the role of CEACAM1 in cancer. Lung Cancer 2008; 60: 309-12.
30. Thies A, Moll I, Berger J, Wagener C, Brummer J, Schulze HJ, et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol 2002; 20: 2530-6.
31. Markel G, Ortenberg R, Seidman R, Sapoznik S, Koren-Morag N, Besser MJ, et al. Systemic dysregulation of CEACAM1 in melanoma patients. Cancer Immunol Immunother 2010; 59: 215-30.
32. Sivan S, Suzan F, Rona O, Tamar H, Vivian B, Tamar P, et al. Serum CEACAM1 correlates with disease progression and survival in malignant melanoma patients. Clin Dev Immunol 2012; 2012: 290536.
33. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
34. Ugurel S, Thirumaran RK, Bloethner S, Gast A, Sucker A, Mueller-Berghaus J, et al. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS ONE 2007; 2: e236.
35. Gast A, Scherer D, Chen B, Bloethner S, Melchert S, Sucker A, et al. Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study. Genes Chromosomes Cancer 2010; 49: 733-45.
36. Hong J, Kandasamy K, Marimuthu M, Choi CS, Kim S. Electrical cellsubstrate impedance sensing as a non-invasive tool for cancer cell study. Analyst 2011; 136: 237-45.
37. Fregni G, Perier A, Pittari G, Jacobelli S, Sastre X, Gervois N, et al. Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy. Clin Cancer Res 2011; 17: 2628-37.
38. Heinemann A, Zhao F, Pechlivanis S, Eberle J, Steinle A, Diederichs S, et al. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res 2012; 72: 460-71.
39. Gambichler T, Grothe S, Rotterdam S, Altmeyer P, Kreuter A. Protein expression of carcinoembryonic antigen cell adhesion molecules in benign and malignant melanocytic skin lesions. Am J Clin Pathol 2009; 131: 782-7.
40. Airola K, Karonen T, Vaalamo M, Lehti K, Lohi J, Kariniemi AL, et al. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer 1999; 80: 733-43.
41. ShumanMoss LA, Jensen-Taubman S, Stetler-Stevenson WG. Matrixmetal-loproteinases: changing roles in tumor progression and metastasis. Am J Pathol 2012; 181: 1895-9.
42. Bourd-Boittin K, Fridman R, Fanchon S, Septier D, Goldberg M, Menashi S. Matrix metalloproteinase inhibition impairs the processing, formation and mineralization of dental tissues during mouse molar development. Exp Cell Res 2005; 304: 493-505.
43. Maekawa K, Sato H, Furukawa M, Yoshizaki T. Inhibition of cervical lymph node metastasis by marimastat (BB-2516)inan orthotopic oral squamous cell carcinoma implantation model. Clin Exp Metastasis 2002; 19: 513-8.
44. Xin ZF, Kim YK, Jung ST. Risedronate inhibits human osteosarcoma cell invasion. J Exp Clin Cancer Res 2009; 28: 105.
45. Ortenberg R, Sapir Y, Raz L, Hershkovitz L, Ben AA, Sapoznik S, et al. Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions. Mol Cancer Ther 2012; 11: 1300-10.
46. Fournes B, Farrah J, Olson M, Lamarche-Vane N, Beauchemin N. Distinct Rho GTPase activities regulate epithelial cell localization of the adhesion molecule CEACAM1: involvement of the CEACAM1 transmembrane domain. Mol Cell Biol 2003; 23: 7291-304.
47. Schumann D, Chen CJ, Kaplan B, Shively JE. Carcinoembryonic antigen cell adhesion molecule 1 directly associates with cytoskeleton proteins actin and tropomyosin. J Biol Chem 2001; 276: 47421-33.
48. Sadekova S, Lamarche-Vane N, Li X, Beauchemin N. The CEACAM1-L glycoprotein associates with the actin cytoskeleton and localizes to cell-cell contact through activation of Rho-like GTPases. Mol Biol Cell 2000; 11: 65-77.
49. Liu G, Atteridge CL, Wang X, Lundgren AD, Wu JD. The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule A independent of A disintegrin and metal-loproteinases. J Immunol 2010; 184: 3346-50.